Skip to main content

Table 4 Analysis of staging related to SPAG5 and NuMA mRNA expression. Clinical stage was determined by the TNM system (tumor size, lymph node involvement, metastasis). According to AJCC guideline, the molecular stage was defined using TNM, tumor grade and ER, PR and HER2 status

From: Investigation of the SPAG5 gene expression and amplification related to the NuMA mRNA levels in breast ductal carcinoma

  N (%) Sum of squares df Mean Square F p value
SPAG5 Clinical stage Stage I 12(30) 102.71 2 51.35 4.50 .018
Stage II 19(47.5)
Stages III and IV 9(22.5)
Molecular stage Stage I 30(75) 2.74 2 1.37 .09 .90
Stage II 5(12.5)
Stages III and IV 5(12.5)
Molecular subtypes Luminal A 12(30) 34.11 3 11.37 .83 .48
Luminal B 22(55)
HER2 positive 2(5)
Basal-like 4(10)
NuMA Clinical stage Stage I 12(30) 4.03 2 2.02 .32 .72
Stage II 19(47.5)
Stages III and IV 9(22.5)
Molecular stage Stage I 30(75) 8.73 2 4.36 .72 .49
Stage II 5(12.5)
Stages III and IV 5(12.5)
Molecular subtypes Luminal A 12(30) 44.97 3 14.99 2.88 .049
Luminal B 22(55)
HER2 positive 2(5)
Basal-like 4(10)
  1. One-way ANOVA was employed to analyze the difference between SPAG5 and NuMA gene expression levels related to clinical stage, molecular stage and molecular subtypes. Normal variable distribution and equality of variances were checked by Kolmogorov-Smirnov and Levene’s test, respectively. Our chosen significance level was 0.05
  2. N number, df degree of freedom, SPAG5 sperm-associated antigen, NuMA nuclear mitotic apparatus protein